

DT05 Rec'd PCT/PT0 1 9 OCT 2004

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. PN0222

SERIAL NO. To Be

Assigned

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT

Bill Clarke, et.al.

FILING DATE Herewith

GROUP 4112

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		<u></u> .	`			
		W-W-		İ	,,,,,,	
					<u> </u>	<u> </u>

FOREIGN PATENT DOCUMENTS

LEXAMINER	DOCUMENT					TRANS	LATION
INITIAL	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
/B.K./	9858272	12-1998	WO				
/B.K./	0035900	06-2000	WO				
/B.K./	0040988	07-2000	WO				
/B.K./	0196895	12-2001	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
/B.K./	Akira, et.al. "Direct nuclear magnetic resonance spectroscopic analysis of (13) C-labeled antipyrine metabolites in human urine" Drug Metabolism and Disposition: The Biological Fate of Chemicals. U.S. 06-2001 vol. 29, No. 6, pages 903-907
/B.K./	Koudriakova, et.al.: "In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats" The Journal of Pharmacology and Experimental Therapeutics. U.S. 12-1996, vol. 279, no. 3, pages 1300-1309
/B.K./	Scott, R.J. et.al., "Determination of a "GW cocktail" of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry: RCM. England 1999 vol. 13, no. 23, pages 2305-2319
/B.K./	Stevens, J.c. et.al.: "Use of the Steroid Derivative RPR 106541 in Combination with Site-directed Mutagenesis for Enhanced Cytochrome P-450 3A4 structure/function analysis" The Journal of Pharmacology and Experimental Therapeutics. US 8-1999 vol. 290, no. 2, pages 594-602
/B.K./	International Search Report for PCT/NO03/001256 dated September 3, 2003
/B.K./	IPER for PCT/NO03/00125 dated March 4, 2004

EXAMINER

/Bryan Kilpatrick/

DATE CONSIDERED

08/20/2008